Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Nutrients

Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease

  • Krystian Krysa1,2
  • Patrycja Musz1
  • Gabriela Ryś1
  • Paulina Serafin1
  • Dawid Wachowiak3
  • Sara Jarmakiewicz-Czaja1,2
  1. 1Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszow, Warzywna 1a, 35-959 Rzeszow, Poland
  2. 2University Center for Research and Development in Health Sciences, University of Rzeszow, Warzywna 1a, 35-959 Rzeszow, Poland
  3. 3Student Scientific Club of Human Nutrition, Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszow, Warzywna 1a, 35-959 Rzeszow, Poland
Read full textPDFDOICite

Abstract

Inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, are chronic inflammatory conditions of the gastrointestinal tract characterized by periods of active disease and remission. Their pathogenesis is multifactorial and involves genetic predisposition, immune response, environmental factors, and alterations in gut microbiota composition and function. Growing evidence suggests that gut microbiota-associated metabolites not only reflect disease activity but also participate in regulating the immune response and maintaining the integrity of the intestinal barrier. The most important groups of metabolites associated with inflammatory bowel diseases include short-chain fatty acids, bile acids, and tryptophan derivatives. Reduced fecal butyrate and acetate concentrations have been reported in inflammatory bowel diseases, although the diagnostic value of fecal short-chain fatty acids remains uncertain. Potential therapeutic approaches include short-chain fatty acid supplementation, particularly sodium butyrate, and dietary interventions aimed at increasing short-chain fatty acid concentrations; however, the clinical efficacy of short-chain fatty acid supplementation remains inconclusive, and evidence for dietary interventions is limited. In the future, the use of gut microbiota metabolites may be based on personalized strategies grounded in multiomic data, enabling precise modulation of the microbiota–metabolite–immune system axis.

Related

  1. Crosstalk between gut microbiota-associated metabolites and adaptive immunity in cholecystitis: a conceptual mechanistic framework and potential therapeutic implications
    Xinqi Wang, Tao Zhang, Zhetan Ren +1
    Frontiers in MicrobiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMC
  2. Gut-kidney axis in chronic kidney disease: Dysbiosis, uremic metabolites and therapeutic opportunities (Review)
    Yinding Wang, Hanyu Zeng, Na Liu +1
    Molecular Medicine ReportsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMC
  3. Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities
    Changsheng Jiang, Wedad M. Nageeb, Shumaila Batool +11
    iSciencePeer-reviewedCC BY12 citedMolecular biology & gene regulationOpenAlex
  4. Gut microbiota- and probiotic-derived bioactive metabolites: mechanisms, evidence, and therapeutic potential in metabolic disorders
    Oghenerobor B. Akpor, Ayotunde O. Ajinde
    Frontiers in Cellular and Infection MicrobiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMCEurope PMC
  5. Progress in research on gut microbiota regulation of tumorigenesis, progression, and therapeutic response via inflammatory cytokines
    Yan Liu, Dan Zang, Jun Chen
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMCCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{krysa2026microbiotaassociated,
  title = {{Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease}},
  author = {Krystian Krysa and Patrycja Musz and Gabriela Ryś and Paulina Serafin and Dawid Wachowiak and Sara Jarmakiewicz-Czaja},
  journal = {Nutrients},
  year = {2026},
  month = oct,
  doi = {10.3390/nu18203372},
  url = {https://www.mdpi.com/2072-6643/18/20/3372},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease
AU  - Krystian Krysa
AU  - Patrycja Musz
AU  - Gabriela Ryś
AU  - Paulina Serafin
AU  - Dawid Wachowiak
AU  - Sara Jarmakiewicz-Czaja
PY  - 2026
DA  - 2026/10/01
JO  - Nutrients
DO  - 10.3390/nu18203372
UR  - https://www.mdpi.com/2072-6643/18/20/3372
AB  - Inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, are chronic inflammatory conditions of the gastrointestinal tract characterized by periods of active disease and remission. Their pathogenesis is multifactorial and involves genetic predisposition, immune response, environmental factors, and alterations in gut microbiota composition and function. Growing evidence suggests that gut microbiota-associated metabolites not only reflect disease activity but also participate in regulating the immune response and maintaining the integrity of the intestinal barrier. The most important groups of metabolites associated with inflammatory bowel diseases include short-chain fatty acids, bile acids, and tryptophan derivatives. Reduced fecal butyrate and acetate concentrations have been reported in inflammatory bowel diseases, although the diagnostic value of fecal short-chain fatty acids remains uncertain. Potential therapeutic approaches include short-chain fatty acid supplementation, particularly sodium butyrate, and dietary interventions aimed at increasing short-chain fatty acid concentrations; however, the clinical efficacy of short-chain fatty acid supplementation remains inconclusive, and evidence for dietary interventions is limited. In the future, the use of gut microbiota metabolites may be based on personalized strategies grounded in multiomic data, enabling precise modulation of the microbiota–metabolite–immune system axis.
SN  - 2072-6643
ER  -